Nyxoah’s Next-Generation Genio 2.1 System Gets CE Mark

Nyxoah has received a CE mark for additional components for its Genio 2.1 system for treatment of patients with obstructive sleep apnea, a respiratory disorder marked by blockage of the upper airway during sleep.

The next-generation system, which includes a new smartphone application and an upgraded external activation chip, provides daily feedback on therapy usage and enables adjustments to the level of stimulation.

Physicians can fine-tune the stimulation to determine the optimal level of comfort for patients without compromising therapy efficacy. The additional features do not require a surgical procedure to replace the implantable component that is already in place, the Belgium-based company said.